Compare ANY & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANY | IMRN |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 12.0M |
| IPO Year | N/A | N/A |
| Metric | ANY | IMRN |
|---|---|---|
| Price | $0.27 | $0.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 441.0K | 84.7K |
| Earning Date | 11-04-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,099,000.00 | $4,777,422.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $29.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 48.63 |
| 52 Week Low | $0.29 | $0.68 |
| 52 Week High | $1.26 | $2.39 |
| Indicator | ANY | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 31.16 | 47.84 |
| Support Level | $0.32 | $1.01 |
| Resistance Level | $0.38 | $1.13 |
| Average True Range (ATR) | 0.03 | 0.10 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 7.16 | 51.72 |
Sphere 3D Corp provides solutions for stand-alone storage and technologies that converge the traditional silos of compute, storage, and network into integrated hyper-converged or converged solution. Its Disk systems include HVE Converged and Hyper-converged Infrastructure. It generates the majority of its revenue from the services it offers. All of its revenue comes from the Americas. The Company has two operating segments: Bitcoin Mining and Service and Product. The Bitcoin Mining segment generates revenue from the digital currency, it earns through its bitcoin mining activities. The Service and Product segment generates revenue from long-term customer contracts for service contracts and extended service contract and the sale of products related to the Company's data storage product line.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.